Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma
Open Access
- 23 April 2011
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 1-10
Abstract
Background: Polyethyleneimine (PEI), which can interact with negatively charged DNA through electrostatic interaction to form nanocomplexes, has been widely attempted to use as a gene delivery system. However, PEI has some defects that are not fit for keeping on gene expression. Therefore, some modifications against PEI properties have been done to improve their application value in gene delivery. In this study, three modified PEI derivatives, including poly(ε-caprolactone)-pluronic-poly(ε-caprolactone) grafted PEI (PCFC-g-PEI), folic acid-PCFC-isophorone diidocyanate-PEI (FA-PEAs) and heparin-PEI (HPEI), were evaluated in terms of their cytotoxicity and transfection efficiency in vitro and in vivo in order to ascertain their potential application in gene therapy. Methods: MTT assay and a marker GFP gene, encoding green fluorescent protein, were used to evaluate cell toxicity and transfection activity of the three modified PEI in vitro. Renal cell carcinoma (RCC) models were established in BALB/c nude mice inoculated with OS-RC-2 cells to detect the gene therapy effects using the three PEI-derived nanoparticles as gene delivery vehicles. The expression status of a target gene Von Hippel-Lindau (VHL) in treated tumor tissues was analyzed by semiquantitative RT-PCR and immunohistochemistry. Results: Each of three modified PEI-derived biomaterials had an increased transfection efficiency and a lower cytotoxicity compared with its precursor PEI with 25-kD or 2-kD molecule weight in vitro. And the mean tumor volume was obviously decreased 30% by using FA-PEAs to transfer VHL plasmids to treat mice RCC models. The VHL gene expression was greatly improved in the VHL-treated group. While there was no obvious tumor inhibition treated by PCFC-g-PEI:VHL and HPEI:VHL complexes. Conclusions: The three modified PEI-derived biomaterials, including PCFC-g-PEI, FA-PEAs and HPEI, had an increased transfection efficiency in vitro and obviously lower toxicities compared with their precursor PEI molecules. The FA-PEAs probably provide a potential gene delivery system to treat RCC even other cancers in future.Keywords
This publication has 32 references indexed in Scilit:
- Honokiol inhibits HepG2 migration via down‐regulation of IQGAP1 expression discovered by a quantitative pharmaceutical proteomic analysisProteomics, 2010
- A novel Poly(ε-caprolactone)-Pluronic-Poly(ε-caprolactone) grafted Polyethyleneimine(PCFC-g-PEI), Part 1, synthesis, cytotoxicity, and in vitro transfection studyBMC Biotechnology, 2009
- In vitro assessments of nanomaterial toxicityAdvanced Drug Delivery Reviews, 2009
- Heparin-conjugated polyethylenimine for gene deliveryJournal of Controlled Release, 2008
- Progress in developing cationic vectors for non-viral systemic gene therapy against cancerBiomaterials, 2008
- Gene expression and methylation status of 14‐3‐3σ in human renal carcinoma tissuesIUBMB Life, 2008
- A tumor‐specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomasCancer Science, 2005
- Tumor Efficacy and Biodistribution of Linear Polyethylenimine-cholesterol/DNA ComplexesMolecular Therapy, 2004
- Modified Linear Polyethylenimine−Cholesterol Conjugates for DNA ComplexationBioconjugate Chemistry, 2003
- Enhancement of the polycation‐mediated DNA uptake and cell transfection with Pluronic P85 block copolymerFEBS Letters, 1996